Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Dauntless Investment Group disclosed in a May 14, 2026, SEC filing that it bought 116,863 shares of Innoviva (NASDAQ:INVA), an estimated $2.52 million trade based on quarterly average pricing.According to a recent SEC filing dated May 14, 2026, Dauntless Investment Group increased its holdings in Innoviva by 116,863 shares during the first quarter. The estimated transaction value was $2.52 million, calculated using the average closing price for the quarter. The stake's quarter-end value rose by $2.74 million, reflecting both the additional shares acquired and changes in the stock price during the period.Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. The company operates at scale within the biotechnology sector, leveraging strategic partnerships to expand its portfolio of respiratory pharmaceuticals. Its business model is built on product commercialization and royalty streams from collaborative agreements. Innoviva’s focus on chronic respiratory diseases and its established alliances position it competitively in the global healthcare market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool